Cyclerion Therapeutics Inc
$ 3.25
1.25%
12 Jun - close price
- Market Cap 14,073,500 USD
- Current Price $ 3.25
- High / Low $ 3.27 / 3.11
- Stock P/E N/A
- Book Value 1.60
- EPS -1.31
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -0.68 %
- 52 Week High 8.48
- 52 Week Low 1.03
About
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$8.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-25 | 2025-11-12 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-14 | 2024-08-07 | 2024-05-07 | 2024-03-05 | 2023-11-13 | 2023-07-28 | 2023-05-11 |
| Reported EPS | -0.19 | -0.3 | -0.11 | -0.5591 | 0.2082 | -0.2862 | -0.5267 | -0.6183 | -0.6847 | 3.1072 | -1.8322 | -3.1957 |
| Estimated EPS | -0.38 | 0 | None | None | None | None | None | None | None | None | -0.28 | -0.3 |
| Surprise | 0.19 | -0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.5522 | -2.8957 |
| Surprise Percentage | 50% | None% | None% | None% | None% | None% | None% | None% | None% | None% | -554.3571% | -965.2333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYCN
2026-05-28 00:10:04
This document provides a company profile and introduction for Cyclerion Therapeutics. Further details about the company's operations, financial health, or strategic initiatives would be found within the full content of such a profile.
2026-05-12 20:39:45
Cyclerion Therapeutics reported a wider net loss of $3.2 million in Q1 2026 with no revenue, while operating expenses rose. The company faces a significant cash crunch, with funds expected to last only into Q3 2026, prompting substantial doubt about its ability to continue as a going concern. A planned merger with Korsana Biosciences, along with a $380 million pre-closing financing, aims to refocus the business on neurodegenerative diseases and provide a Contingent Value Rights Agreement for existing shareholders to capture value from legacy assets.
2026-05-07 14:39:35
FMR LLC has reported a 15.0% beneficial ownership stake in Cyclerion Therapeutics (NASDAQ: CYCN), as detailed in a Schedule 13G filing. The investment firm beneficially owns 649,547 shares of common stock as of April 30, 2026, with sole dispositive power. This includes holdings by Fidelity Growth Company Commingled Pool (6.6%) and Fidelity Growth Company Fund (5.0%).
2026-05-04 22:39:30
Halper Sadeh LLC, an investor rights law firm, is investigating Organon & Co. (OGN), TruBridge, Inc. (TBRG), and Cyclerion Therapeutics, Inc. (CYCN) for potential violations of federal securities laws and breaches of fiduciary duties related to their recent or proposed transactions. The firm suggests that insiders may receive substantial financial benefits not available to ordinary shareholders and that the deals may limit superior competing offers. Halper Sadeh LLC encourages shareholders to contact them to discuss their legal rights and options, offering to seek increased consideration, additional disclosures, or other relief.
2026-05-03 06:11:00
This page provides an overview of insider trading activity for Cyclerion Therapeutics, Inc. (CYCN), alongside other financial data. It indicates no recent insider trading by directors and management, and no congressional trading data for the ticker. The article also lists significant patent grants and includes company information such as market cap and employee count.
2026-04-30 12:39:14
Cyclerion Therapeutics filed an amended annual report (10-K/A) to provide detailed disclosures on its board structure, executive compensation, and share ownership, which were previously omitted. The report highlights an independent chairman, three key board committees, and policies covering risk oversight, insider trading, and clawbacks. It also details 2025 compensation for CEO Regina Graul and CFO Rhonda Chicko, a March 2025 private placement, and the anticipated third-quarter 2026 merger with Korsana Biosciences.
